W K Alfred Alfred Yung


Ontology type: schema:Person     


Person Info

NAME

W K Alfred Alfred

SURNAME

Yung

Publications in SciGraph latest 50 shown

  • 2019-11-27 A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma in JOURNAL OF NEURO-ONCOLOGY
  • 2018-02-05 NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients in JOURNAL OF NEURO-ONCOLOGY
  • 2017-10-07 Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02 in JOURNAL OF NEURO-ONCOLOGY
  • 2016-07-12 A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma in JOURNAL OF NEURO-ONCOLOGY
  • 2015-09-01 Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma in ACTA NEUROPATHOLOGICA
  • 2014-05-07 Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma in JOURNAL OF NEURO-ONCOLOGY
  • 2013-06-13 Bevacizumab use in disseminated choroid plexus papilloma in JOURNAL OF NEURO-ONCOLOGY
  • 2012-10-20 A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806) in JOURNAL OF NEURO-ONCOLOGY
  • 2012-03-18 Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study in JOURNAL OF NEURO-ONCOLOGY
  • 2012-03-07 Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-01-09 Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison in JOURNAL OF NEURO-ONCOLOGY
  • 2009-08-11 Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme in BRITISH JOURNAL OF CANCER
  • 2009-06-28 Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma in JOURNAL OF NEURO-ONCOLOGY
  • 2009-03-07 Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma in JOURNAL OF NEURO-ONCOLOGY
  • 2008-03-04 Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation in JOURNAL OF NEURO-ONCOLOGY
  • 2007-01-18 PTEN down regulates AP-1 and targets c-fos in human glioma cells Via PI3-kinase/Akt pathway in MOLECULAR AND CELLULAR BIOCHEMISTRY
  • 2006-09-22 A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme in JOURNAL OF NEURO-ONCOLOGY
  • 2006-04-25 Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status in JOURNAL OF NEURO-ONCOLOGY
  • 2005-11-29 Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme in JOURNAL OF NEURO-ONCOLOGY
  • 2005-07-06 Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro in BREAST CANCER RESEARCH
  • 2005-02 PAX6 suppresses growth of human glioblastoma cells in JOURNAL OF NEURO-ONCOLOGY
  • 2005-01-14 Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization in CANCER GENE THERAPY
  • 2001-10-19 Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN in ONCOGENE
  • 2000-05 Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades in CLINICAL & EXPERIMENTAL METASTASIS
  • 2000-01-20 A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo in ONCOGENE
  • 1999-12 Neurologic complications of cancer therapy in CURRENT TREATMENT OPTIONS IN NEUROLOGY
  • 1998-07 Biological Response Modifiers in the Treatment of Malignant Brain Tumours in CNS DRUGS
  • 1998-06 Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo in NATURE MEDICINE
  • 1998-01 Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity. in JOURNAL OF NEUROVIROLOGY
  • 1998 Tumor Suppressor Gene Therapy for Brain Tumors in GENE THERAPY FOR NEUROLOGICAL DISORDERS AND BRAIN TUMORS
  • 1997-12 The autocrine loop of TGF-α/EGFR and brain tumors in JOURNAL OF NEURO-ONCOLOGY
  • 1997-10-23 Tumor Suppressor Gene Therapy for Brain Tumors in GENE THERAPY FOR NEUROLOGICAL DISORDERS AND BRAIN TUMORS
  • 1997-09 The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin) in JOURNAL OF NEURO-ONCOLOGY
  • 1997-09 All-trans-retinoic acid: a phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma in JOURNAL OF NEURO-ONCOLOGY
  • 1997-04 Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers in NATURE GENETICS
  • 1996-10 Resolution of recurrent malignant ganglioglioma after treatment with Cis-retinoic acid in JOURNAL OF NEURO-ONCOLOGY
  • 1993-10 Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy in JOURNAL OF NEURO-ONCOLOGY
  • 1992-02 Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas in JOURNAL OF NEURO-ONCOLOGY
  • 1990-08 A pilot study of recombinant interferon beta (IFN-βser) in patients with recurrent glioma in JOURNAL OF NEURO-ONCOLOGY
  • 1989-12 The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen in JOURNAL OF NEURO-ONCOLOGY
  • 1989-09 Intravenous BCNU and AZQ in patients with recurrent malignant gliomas in JOURNAL OF NEURO-ONCOLOGY
  • 1987-12 Intracarotid VP-16 in malignant brain tumors in JOURNAL OF NEURO-ONCOLOGY
  • 1985-03 Vimentin and glial fibrillary acidic protein in human brain tumors in JOURNAL OF NEURO-ONCOLOGY
  • 1984-03 A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors in JOURNAL OF NEURO-ONCOLOGY
  • 1983-06 A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas in JOURNAL OF NEURO-ONCOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412647.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.55460.32", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418701.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.240372.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.170205.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.48336.3a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.27755.32", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.16753.36", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412587.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.267309.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.34477.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.17063.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.32224.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.240684.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413103.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411918.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.28803.31", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.65499.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.51462.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.424926.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411730.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.478063.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.62560.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.19006.3e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.21925.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.214458.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411947.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.26009.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.477750.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.66875.3a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416214.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412590.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.266102.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417747.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5386.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.21107.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.94365.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.267313.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.38142.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.241054.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.34421.30", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417538.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.267308.8", 
            "type": "Organization"
          }
        ], 
        "familyName": "Yung", 
        "givenName": "W K Alfred Alfred", 
        "id": "sg:person.016341673457.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016341673457.32"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2021-12-01T20:43", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/person/person_911.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.016341673457.32'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.016341673457.32'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.016341673457.32'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.016341673457.32'


     

    This table displays all metadata directly associated to this object as RDF triples.

    102 TRIPLES      10 PREDICATES      54 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.016341673457.32 schema:affiliation Nd8fe7f8ae256471e817a3ed553074104
    2 grid-institutes:grid.16753.36
    3 grid-institutes:grid.170205.1
    4 grid-institutes:grid.17063.33
    5 grid-institutes:grid.19006.3e
    6 grid-institutes:grid.21107.35
    7 grid-institutes:grid.214458.e
    8 grid-institutes:grid.21925.3d
    9 grid-institutes:grid.240372.0
    10 grid-institutes:grid.240684.c
    11 grid-institutes:grid.241054.6
    12 grid-institutes:grid.26009.3d
    13 grid-institutes:grid.266102.1
    14 grid-institutes:grid.267308.8
    15 grid-institutes:grid.267309.9
    16 grid-institutes:grid.267313.2
    17 grid-institutes:grid.27755.32
    18 grid-institutes:grid.28803.31
    19 grid-institutes:grid.32224.35
    20 grid-institutes:grid.34421.30
    21 grid-institutes:grid.34477.33
    22 grid-institutes:grid.38142.3c
    23 grid-institutes:grid.411730.0
    24 grid-institutes:grid.411918.4
    25 grid-institutes:grid.411947.e
    26 grid-institutes:grid.412587.d
    27 grid-institutes:grid.412590.b
    28 grid-institutes:grid.412647.2
    29 grid-institutes:grid.413103.4
    30 grid-institutes:grid.416214.4
    31 grid-institutes:grid.417538.c
    32 grid-institutes:grid.417747.6
    33 grid-institutes:grid.418701.b
    34 grid-institutes:grid.424926.f
    35 grid-institutes:grid.477750.6
    36 grid-institutes:grid.478063.e
    37 grid-institutes:grid.48336.3a
    38 grid-institutes:grid.51462.34
    39 grid-institutes:grid.5386.8
    40 grid-institutes:grid.55460.32
    41 grid-institutes:grid.62560.37
    42 grid-institutes:grid.65499.37
    43 grid-institutes:grid.66875.3a
    44 grid-institutes:grid.94365.3d
    45 schema:familyName Yung
    46 schema:givenName W K Alfred Alfred
    47 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016341673457.32
    48 schema:sdDatePublished 2021-12-01T20:43
    49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    50 schema:sdPublisher N891f1752d402457497556dcacffd5663
    51 sgo:license sg:explorer/license/
    52 sgo:sdDataset persons
    53 rdf:type schema:Person
    54 N891f1752d402457497556dcacffd5663 schema:name Springer Nature - SN SciGraph project
    55 rdf:type schema:Organization
    56 Nd8fe7f8ae256471e817a3ed553074104 schema:affiliation grid-institutes:grid.240145.6
    57 sgo:isCurrent true
    58 rdf:type schema:OrganizationRole
    59 grid-institutes:grid.16753.36 schema:Organization
    60 grid-institutes:grid.170205.1 schema:Organization
    61 grid-institutes:grid.17063.33 schema:Organization
    62 grid-institutes:grid.19006.3e schema:Organization
    63 grid-institutes:grid.21107.35 schema:Organization
    64 grid-institutes:grid.214458.e schema:Organization
    65 grid-institutes:grid.21925.3d schema:Organization
    66 grid-institutes:grid.240145.6 schema:Organization
    67 grid-institutes:grid.240372.0 schema:Organization
    68 grid-institutes:grid.240684.c schema:Organization
    69 grid-institutes:grid.241054.6 schema:Organization
    70 grid-institutes:grid.26009.3d schema:Organization
    71 grid-institutes:grid.266102.1 schema:Organization
    72 grid-institutes:grid.267308.8 schema:Organization
    73 grid-institutes:grid.267309.9 schema:Organization
    74 grid-institutes:grid.267313.2 schema:Organization
    75 grid-institutes:grid.27755.32 schema:Organization
    76 grid-institutes:grid.28803.31 schema:Organization
    77 grid-institutes:grid.32224.35 schema:Organization
    78 grid-institutes:grid.34421.30 schema:Organization
    79 grid-institutes:grid.34477.33 schema:Organization
    80 grid-institutes:grid.38142.3c schema:Organization
    81 grid-institutes:grid.411730.0 schema:Organization
    82 grid-institutes:grid.411918.4 schema:Organization
    83 grid-institutes:grid.411947.e schema:Organization
    84 grid-institutes:grid.412587.d schema:Organization
    85 grid-institutes:grid.412590.b schema:Organization
    86 grid-institutes:grid.412647.2 schema:Organization
    87 grid-institutes:grid.413103.4 schema:Organization
    88 grid-institutes:grid.416214.4 schema:Organization
    89 grid-institutes:grid.417538.c schema:Organization
    90 grid-institutes:grid.417747.6 schema:Organization
    91 grid-institutes:grid.418701.b schema:Organization
    92 grid-institutes:grid.424926.f schema:Organization
    93 grid-institutes:grid.477750.6 schema:Organization
    94 grid-institutes:grid.478063.e schema:Organization
    95 grid-institutes:grid.48336.3a schema:Organization
    96 grid-institutes:grid.51462.34 schema:Organization
    97 grid-institutes:grid.5386.8 schema:Organization
    98 grid-institutes:grid.55460.32 schema:Organization
    99 grid-institutes:grid.62560.37 schema:Organization
    100 grid-institutes:grid.65499.37 schema:Organization
    101 grid-institutes:grid.66875.3a schema:Organization
    102 grid-institutes:grid.94365.3d schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...